Inclusion Criteria:

- At least 18 years of age with life expectancy of 3 months

- Evaluable, histologically or cytologically confirmed, refractory advanced solid tumor
malignancy

- ECOG score of less than or equal to 1

- Adequate hematologic function (absolute neutrophil count [ANC] greater than or equal
to 1,500 cells/uL; hemoglobin greater than or equal to 9 g/dL; platelets greater than
or equal to 100,000/uL and less than or equal to 500,000/uL)

- Adequate renal function (serum creatinine less than or equal to 1.5 mg/dL or
calculated creatinine clearance greater than 60 mL/min)

- Adequate hepatic function (bilirubin less than or equal to 1.5 x ULN; ALT less than
or equal to 3 x ULN; AST less than or equal to 3 x ULN)

- Normal coagulation profile (prothrombin time/international normalized ratio [PT/INR]
and activated partial thromboplastin time [aPTT] within institutional normal limits)

- D-dimer less than or equal to 2 times upper limit of institutional normal

- New York Heart Association classification I or II for patients with significant
cardiopulmonary disease

- Female patients must have a negative serum pregnancy test at prestudy and all
patients of reproductive potential must be willing to use an approved form of barrier
method contraception

Exclusion Criteria:

- Prior exposure to any chimeric antibody

- Any evidence of clinically significant bleeding

- Known history of bleeding diathesis or coagulopathy

- Any history of thromboembolic events including central venous catheter-related
thrombosis within the past 12 months

- Any evidence or history of hypercoagulable state (eg, shortened aPTT)

- Concurrent therapy with oral or parenteral anticoagulants

- Concurrent hormone therapy (ie, estrogen contraceptives, hormone replacement,
anti-estrogen)

- Chemotherapy, immunotherapy or radiotherapy within 4 weeks of day 0 (6 weeks for
nitrosoureas and mitomycin C) or have not recovered from treatment-related side
effects due to agents administered more than 4 weeks earlier (stable,
non-hematological residual toxicities of Grade 1 or less and Grade 2 dry skin or
alopecia are allowed)

- Investigational therapy within 4 weeks of day 0

- Evidence of central nervous system (CNS) metastatic disease at prestudy (no active
brain metastases on magnetic resonance imaging [MRI] at prestudy)

- Major surgery within 4 weeks of day 0

- Pregnant or nursing women

- Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease)

- Any history of angina pectoris, coronary artery disease or cerebrovascular accident,
or transient ischemic attack

- A history of any condition requiring anti-platelet therapy with the exception of
general cardiovascular prophylaxis with aspirin

- A history of any condition requiring treatment (past or current) with coumarin-type
agents within the past 12 months

- Cardiac arrhythmia requiring medical therapy

- Serious non-healing wound

- Requirement for chronic daily treatment with non-steroidal anti-inflammatory drugs
(NSAIDs), anti-platelet drugs (eg, phosphodiesterase inhibitors, adenosine
diphosphate receptor antagonists) or steroids

- Known chronic infection with HIV or hepatitis